Research programme: protein-based hemojuvelin inhibitors - Xenon PharmaceuticalsAlternative Names: HJV inhibitors - Roche/Xenon
Latest Information Update: 02 Jun 2010
At a glance
- Originator Xenon Pharmaceuticals
- Class Proteins
- Mechanism of Action HFE2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Anaemia
Most Recent Events
- 02 Jun 2010 Early research is ongoing in Canada
- 08 Dec 2006 Early research in Anaemia in Canada (unspecified route)